Group 27
Wing Yan Hoh
Dominique Daeshon Stewart
Areeb Iqbal
Quinn Takashi Korematsu
Carol Chen
Annotated Bibliography
American Cancer Society. (http://www.cancer.org)
National Cancer Institute (www.cancer.gov)
Schwabb, M. (Ed.) (2012). Acute Myeloid Cancer. In Encyclopedia of Cancer. (pp. 29-32). Heidelberg, Germany: Springer.
Surveillance, Epidemiology, and End Results Program (seer.cancer.gov)
Leukemia & Lymphoma Society (https://www.lls.org)
Adamia S., Bar-Natan M., et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 123(18), 2816-25(2014). PMID 24574459
When observing splicing of RNA in cells of AML patients, scientists observed abnormal spliced genes of NOTCH2 and FLT3. These genes hold the blueprint for myeloid cell surface proteins. This abnormality is present in over 70% of AML patients, suggesting that it may be responsible for the production of proteins with malignant functions. May also correlate to the progression of AML. NOTCH2 and FLT3 may used as biomarkers in treatments like FISH and PCR.
Rothe K., Lin H., et al. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123(23), 3622-34(2014). PMID 24755409
Current treatment of Imatinib mesylate (IM) triggers autophagy in CML. …show more content…
The main treatment method discussed is the allogeneic hematopoietic cell transplantation (HCT), a perilous treatment method that often results in death of the patient. Researches have been studying the link between MRD and the relapse of acute myeloid leukemia, in order to use MRD levels as a predictor of post-HCT relapse. This information can then be used to aid physicians in making a better decision for the course of the treatment of patients with acute myeloid
Wing Yan Hoh
Dominique Daeshon Stewart
Areeb Iqbal
Quinn Takashi Korematsu
Carol Chen
Annotated Bibliography
American Cancer Society. (http://www.cancer.org)
National Cancer Institute (www.cancer.gov)
Schwabb, M. (Ed.) (2012). Acute Myeloid Cancer. In Encyclopedia of Cancer. (pp. 29-32). Heidelberg, Germany: Springer.
Surveillance, Epidemiology, and End Results Program (seer.cancer.gov)
Leukemia & Lymphoma Society (https://www.lls.org)
Adamia S., Bar-Natan M., et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 123(18), 2816-25(2014). PMID 24574459
When observing splicing of RNA in cells of AML patients, scientists observed abnormal spliced genes of NOTCH2 and FLT3. These genes hold the blueprint for myeloid cell surface proteins. This abnormality is present in over 70% of AML patients, suggesting that it may be responsible for the production of proteins with malignant functions. May also correlate to the progression of AML. NOTCH2 and FLT3 may used as biomarkers in treatments like FISH and PCR.
Rothe K., Lin H., et al. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123(23), 3622-34(2014). PMID 24755409
Current treatment of Imatinib mesylate (IM) triggers autophagy in CML. …show more content…
The main treatment method discussed is the allogeneic hematopoietic cell transplantation (HCT), a perilous treatment method that often results in death of the patient. Researches have been studying the link between MRD and the relapse of acute myeloid leukemia, in order to use MRD levels as a predictor of post-HCT relapse. This information can then be used to aid physicians in making a better decision for the course of the treatment of patients with acute myeloid